Biaryl Inhibitors Targeting Bruton's Tyrosine Kinase Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant need for effective inhibitors of Bruton's tyrosine kinase (Btk) due to its critical role in B-cell and T-cell signaling, particularly in autoimmune disorders and immunodeficiencies like X-linked agammaglobulinemia.
Innovation Solution
Development of specific compounds of formula I, which are pharmaceutically acceptable salts, designed to inhibit Btk activity by targeting its enzymatic function, with defined structural parameters for R1, R2, R3, R4, R5, Q1, Q2, Q3, A1, A2, and A3 groups to form a potent inhibitor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule compounds are used to inhibit Btk, then the inhibitor can penetrate cell membranes and reach intracellular targets, but achieving high selectivity and potency against Btk compared to other Tec kinases becomes challenging
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups (R1-R5, Q1-Q3, A1-A3) at particular positions on the biaryl core structure. These localized modifications create specific interaction points with Btk's active site while maintaining the overall molecular framework, enabling selective inhibition of Btk over other Tec kinases through targeted local interactions rather than requiring complete structural redesign
Solution Approach 2:
The patent employs parameter changes by systematically varying substituent parameters (different R groups, Q groups, and A group configurations) on the biaryl core to optimize Btk inhibition. By adjusting these molecular parameters while keeping the core structure constant, the invention achieves high potency and selectivity through incremental optimization rather than complex structural changes
2Reliability
If highly potent Btk inhibitors are developed, then therapeutic efficacy improves, but potential off-target effects and toxicity may increase
Solution Approach 1:
The patent uses local quality to create specific molecular recognition elements through substituted groups on the biaryl core. These localized features enable the inhibitor to distinguish Btk from other kinases by forming specific interactions with unique residues in Btk's binding pocket, thereby achieving high therapeutic efficacy while minimizing off-target effects through precise local molecular recognition
Solution Approach 2:
The biaryl core structure acts as an intermediary framework that mediates between the need for high potency and low toxicity. By providing a stable, well-defined core structure with controllable substituents, it enables the design of inhibitors that achieve high Btk selectivity through controlled molecular interactions, reducing the likelihood of off-target binding while maintaining therapeutic efficacy
Data Source
AI summary
The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.